Tata Consultancy Services' Cloud-based ADD Suite Received the Recognition for Leveraging Automation, AI and IoT to Digitally Transform Clinical Trials
Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS), a leading global IT services, consulting, and business solutions organization, announced that its cloud-based clinical solutions and services suite, TCS Advanced Drug Development (ADD), has won an award in the category Excellence in Ancillary Pharma Services, at the India Pharma Awards 2019.
The India Pharma Awards bring together industry pioneers and recognize outstanding examples of innovation that improve the pharma industry. TCS was recognized for its leadership in leveraging automation, artificial intelligence (AI) and IoT through its intellectual property and commercial-off-the-shelf offerings, to digitize and transform patient engagement, metadata management and regulatory submissions for life sciences organizations.
"We are building future-proof technology platforms to transform drug development by harnessing our deep knowledge of the life sciences industry, coupled with expertise in digital and AI technologies," said Debashis Ghosh, Global Head, Life Sciences and Healthcare, TCS. "This award is a testament to the advanced capabilities of our TCS ADD suite that digitally transforms clinical trials and delivers increased speed to market, improved regulatory compliance and enhanced patient experiences."
TCS ADD is a suite of cloud-based platforms adopted by 18 leading global life sciences companies to transform their product innovation initiatives. It streamlines the entire clinical R&D value chain, spanning clinical data management, metadata management, pharmacovigilance, patient engagement, clinical operations, and data analytics and insights. The suite fosters optimized study planning, accelerates study setup and execution, manages comprehensive and new data sources, derives meaningful insights, enables adherence to safety and regulatory needs, improves patient engagement, and supports adaptive trials.
The suite is powered by a cognitive engine called 'Decision Fabric' that enables the automation of complex business processes. It leverages cloud architecture and intuitive user experience design and aligns to the Good Clinical Practice guidelines and privacy regulations.
Shares of TATA CONSULTANCY SERVICES LTD. was last trading in BSE at Rs.2122.95 as compared to the previous close of Rs. 2121.5. The total number of shares traded during the day was 184863 in over 5191 trades.
The stock hit an intraday high of Rs. 2130 and intraday low of 2101. The net turnover during the day was Rs. 391025613.